These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14610383)

  • 1. Are statins indicated for the primary prevention of coronary heart disease in octogenarians? protagonist viewpoint.
    Stone NJ
    Am J Geriatr Cardiol; 2003; 12(6):351-6. PubMed ID: 14610383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
    Ridker PM; Rifai N; Clearfield M; Downs JR; Weis SE; Miles JS; Gotto AM;
    N Engl J Med; 2001 Jun; 344(26):1959-65. PubMed ID: 11430324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who should receive statin therapy among the elderly?
    Desilvey DL
    Am J Geriatr Cardiol; 2006; 15(2):122. PubMed ID: 16525228
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing the next event in the elderly: the PROSPER perspective.
    Shepherd J
    Atheroscler Suppl; 2003 Dec; 4(5):17-22. PubMed ID: 14980231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are statins indicated for the primary prevention of CAD in octogenarians? antagonist viewpoint.
    Foody JM; Krumholz HM
    Am J Geriatr Cardiol; 2003; 12(6):357-60. PubMed ID: 14610384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering drugs and heart failure: where do we go after the statin trials?
    Strandberg TE
    Curr Opin Cardiol; 2010 Jul; 25(4):385-93. PubMed ID: 20549843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?
    Watts GF
    Eur Heart J; 2004 May; 25(9):716-9. PubMed ID: 15120879
    [No Abstract]   [Full Text] [Related]  

  • 15. Ongoing clinical trials of statins.
    Gotto AM
    Am J Cardiol; 2001 Aug; 88(4A):36F-40F. PubMed ID: 11520486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M
    MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
    [No Abstract]   [Full Text] [Related]  

  • 17. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ; Watson KE; Weiss RE; Fonarow GC
    Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.